Ganitumab clinical trials
Also written AMG 479.
How each study uses ganitumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ganitumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
29 studies that test it; most in 2009 (6)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 6 |
| 2010 | 4 |
| 2011 | 2 |
| 2012 | 6 |
| 2014 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 13
NantCell, Inc. (9) · NantBioScience, Inc. (3) · National Cancer Institute (NCI) (2) · Amgen (2) · Dana-Farber Cancer Institute (2) · Translational Research in Oncology (2) · M.D. Anderson Cancer Center (2) · Jeffrey Clarke (1)
Often tested with
Tested in the same studies.
Conatumumab (4) · Panitumumab (2) · Rilotumumab (2) · Everolimus (2) · Doxorubicin (1) · Ifosfamide (1) · Irinotecan (1) · Pazopanib (1)
Studies
Open first, then newest update. How each study uses ganitumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 29
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaRecruitingNot applicableM.D. Anderson Cancer CenterNCT04199026Written as GanitumabHow we know
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as AMG 479 (Ganitumab) plus MetforminHow we know
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing SarcomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02306161Written as GanitumabHow we know
- Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the PancreasTerminatedPhase 2NantBioScience, Inc.NCT01318642Written as AMG 479How we know
- QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic CancerCompletedPhase 1/2NantCell, Inc.NCT00630552Written as AMG 479How we know
- QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung CancerTerminatedPhase 1/2NantCell, Inc.NCT00807612Written as AMG 479How we know
- QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast CancerCompletedPhase 2NantCell, Inc.NCT00626106Written as AMG 479How we know
- QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung CancerTerminatedPhase 1/2NantCell, Inc.NCT00791154Written as AMG 479How we know
- QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid TumorsTerminatedPhase 1/2NantCell, Inc.NCT00819169Written as AMG 479How we know
- Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)CompletedPhase 1/2NantBioScience, Inc.NCT00788957Written as GanitumabHow we know
- Palbociclib + Ganitumab In Ewing SarcomaTerminatedPhase 2Dana-Farber Cancer InstituteNCT04129151Written as GanitumabHow we know
- Study to Evaluate Mechanisms of Acquired Resistance to PanitumumabCompletedPhase 2NantBioScience, Inc.NCT00891930Written as GanitumabHow we know
- QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the PancreasCompletedPhase 3NantCell, Inc.NCT01231347Written as AMG 479How we know
- Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar RhabdomyosarcomaTerminatedPhase 1/2National Cancer Institute (NCI)NCT03041701Written as GanitumabHow we know
- Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)CompletedPhase 2AmgenNCT01327612Written as GanitumabHow we know
- A Study of MEK162 and AMG 479 in Patients With Selected Solid TumorsTerminatedPhase 1/2PfizerNCT01562899Written as AMG 479How we know
- A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007CompletedPhase 1Jeffrey ClarkeNCT01061788Written as AMG 479, Everolimus, PanitumumabHow we know
- A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid TumorsTerminatedPhase 1/2Novartis PharmaceuticalsNCT01708161Written as AMG 479How we know
- AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine TumorsCompletedPhase 2Dana-Farber Cancer InstituteNCT01024387Written as AMG 479How we know
- Study of RAD001 + AMG479 for Patients With Advanced Solid TumorsCompletedPhase 1Shadia JalalNCT01122199Written as RAD001 + AMG479How we know
Codes
What other systems call ganitumab · ClinicalTrials.gg INT005541
- MeSH (NLM) C545764ganitumabConfirmed NLM, Wikidata
- UNII (FDA) CK1441RCZ8GANITUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q5521322ganitumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71531GanitumabOne source FDA
- DrugBank DB12205One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C545764 | ganitumab | Confirmed NLM, Wikidata |
| UNII (FDA) | CK1441RCZ8 | GANITUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5521322 | ganitumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71531 | Ganitumab | One source FDA |
| DrugBank | DB12205 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.